The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Early diagnostic value of survivin and its alternative splice variants in breast cancer
Open accessAbstract
Background: The inhibitor of apoptosis (IAP) protein Survivin and its splice variants are differentially expressed in breast cancer tissues. Our previous work showed Survivin is released from tumor cells via small membrane-bound vesicles called exosomes. We, therefore, hypothesize that analysis of serum exosomal Survivin and its splice variants may provide a novel biomarker for early diagnosis of breast cancer. Methods: We collected sera from forty breast cancer patients and ten control patients who were disease free for 5 years after treatment. In addition, twenty-three paired breast cancer tumor tissues from those same 40 patients were analyzed for splice variants. Serum levels of Survivin were analyzed using ELISA and exosomes were isolated from this serum using the commercially available ExoQuick kit, with subsequent Western blots and immunohistochemistry performed. Results: Survivin levels were significantly higher in all the breast cancer samples compared to controls (p < 0.05) with exosome amounts significantly higher in cancer patient sera compared to controls (p < 0.01). While Survivin and Survivin-∆Ex3 splice variant expression and localization was identical in serum exosomes, differential expression of Survivin-2B protein existed in the exosomes. Similarly, Survivin and Survivin-∆Ex3 proteins were the predominant forms detected in all of the breast cancer tissues evaluated in this study, whereas a more variable expression of Survivin-2B level was found at different cancer stages. Conclusion: In this study we show for the first time that like Survivin, the Survivin splice variants are also exosomally packaged in the breast cancer patients’ sera, mimicking the survivin splice variant pattern that we also report in breast cancer tissues. Differential expression of exosomal-Survivin, particularly Survivin-2B, may serve as a diagnostic and/or prognostic marker, a “liquid biopsy” if you will, in early breast cancer patients. Furthermore, a more thorough understanding of the role of this prominent antiapoptotic pathway could lead to the development of potential therapeutics for breast cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Cited by
Role of exosomal proteins in cancer diagnosis
Li, W., Li, C., Zhou, T., Liu, X., Liu, X., Li, X., & Chen, D. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0706-8 · Cited by 447
Exosomes in Cancer Diagnostics
Soung, Y., Ford, S., Zhang, V., & Chung, J. (2017) · Cancers · doi:10.3390/cancers9010008 · Cited by 368
Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer
Sandfeld-Paulsen, B., Jakobsen, K. R., Bæk, R., Folkersen, B. H., Rasmussen, T. R., Meldgaard, P., Varming, K., Jørgensen, M. M., & Sorensen, B. S. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.034 · Cited by 311
Internalization of Exosomes through Receptor-Mediated Endocytosis
Gonda, A., Kabagwira, J., Senthil, G. N., & Wall, N. R. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0891 · Cited by 296
Self-citationCurrent Progresses of Exosomes as Cancer Diagnostic and Prognostic Biomarkers
Huang, T., & Deng, C.-X. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.27796 · Cited by 228
Metadata
- Authors
- Khan, S., Bennit, H. F., Turay, D., Perez, M., Mirshahidi, S., Yuan, Y., & Wall, N. R.
- Venue
- BMC Cancer
- Published
- 2014-03-12
- Volume
- 14
- Issue
- 1
- Pages
- 176-176
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W1968440214
- Cited by
- 209
- References
- 1
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early diagnostic value of survivin and its alternative splice variants in breast cancer. https://app.cochat.ai/papers/10.1186/1471-2407-14-176
- The paper
- Khan, S., Bennit, H. F., Turay, D., Perez, M., Mirshahidi, S., Yuan, Y., & Wall, N. R. (2014). Early diagnostic value of survivin and its alternative splice variants in breast cancer. BMC Cancer. https://doi.org/10.1186/1471-2407-14-176
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.